facility karkhadi gujarat produces cephalosporins class âlactam antibiotics filing bombay stock exchange morning sun pharmaceutical industries announced unit placed import alert us food drug administration fda
alert issued following inspection us agency identified noncompliance current good manufacturing practice cgmp regulations thus drugs made facility may detained without physical examination time fda satisfied appearance violation removed either reinspection submission appropriate documentation responsible fda center
sun pharma spokesperson mira desai told inpharmatechnologistcom alert negligible impact companywide revenues would unlikely cause shortages us
furthermore confirmed firm already initiated several corrective steps address observations made fda unable provide details
shares firm fell 5 following announcement
news sees sun pharma join growing list high profile indian drugmakers products headed us banned due gmp violations
four ranbaxys facilities india subject alert c api plant toansa becoming latest fall ban january whilst two wockhardt facilities fell import ban last year
fda spoken length ensuring quality indian suppliers commissioner margaret hamburg visited country last month part address issue statement intent signed pledging cooperation ensuring compliance us indian authorities fda also said would number inspectors country
specific import alert 6640 cites 33 facilities india product imports banned however whilst much recent emphasis india 31 facilities china also affected ban next largest country germany eight plants banned exporting drugs us
antibiotic producing facility run sun pharma hit import alert us fda latest blow indian drug exporters
facility karkhadi gujarat dedicated producing cephalosporins class âlactam antibiotics filing bombay stock exchange morning sun pharmaceutical industries announced unit placed import alert us food drug administration fda
alert issued following inspection plant agency identified noncompliance current good manufacturing practice cgmp regulations thus drugs made facility may detained without physical examination time fda satisfied appearance violation removed either reinspection submission appropriate documentation responsible fda center
sun pharma spokesperson mira desai told inpharmatechnologistcom alert negligible impact companywide revenues would unlikely cause shortages us
furthermore confirmed firm already initiated several corrective steps address observations made fda unable provide details
shares firm fell 5 following announcement
news sees sun pharma join growing list high profile indian drugmakers products headed us banned due gmp violations
four ranbaxys facilities india subject alert c api plant toansa becoming latest fall ban january whilst two wockhardt facilities fell import ban last year
fda spoken length ensuring quality indian suppliers commissioner margaret hamburg visited country last month part address issue statement intent signed pledging cooperation ensuring compliance us indian authorities fda also said would number inspectors country
specific import alert 6640 cites 33 facilities india product imports banned however whilst much recent emphasis india 31 facilities china also affected ban next largest country germany eight plants banned exporting drugs us
